The EBMT/EHA CAR-T Cell Handbook

1. Structure of and Signalling Through Chimeric Antigen Receptor
2. Genetic Engineering of Autologous or Allogeneic Immune Effector Cells
3. What Defines a Good Tumour Antigen?
4. Tumour Escape from CAR-T Cells
5. CART Initiatives in Europe
6. Providing the Starting Material to the Manufacturer of an Approved and Commercially Available Autologous CAR-T Cell Treatment
7. Receiving, Handling, Storage, Thawing, Distribution, and Administration of CAR-T Cells Shipped from the Manufacturing Facility
8. Point-of-Care Production of CAR-T Cells
9. Off-the-Shelf Allogeneic CAR-T Cells or Other Immune Effector Cells
10. Paediatric Acute Lymphoblastic Leukaemia (ALL)
11. Adult Acute Lymphoblastic Leukaemia
12. Diffuse Large B Cell Lymphoma and Primary Mediastinal Lymphoma
13. Mantle Cell Lymphoma
14. Chronic Lymphocytic Leukaemia
15. Indolent Lymphomas
16. Multiple Myeloma
17. Developments in Other Haematological Malignancies: Other Lymphoid Malignancies
18. Myeloid Malignancies
19. Developments in Solid Tumours
20. Bridging Chemotherapy: Adult Acute Lymphoblastic Leukaemia
21. Bridging to CAR-T Cells in Children, Adolescents, and Young Adults with ALL
22. Bridging Chemotherapy: Relapsed/Refractory Aggressive B-Cell Lymphoma
23. Bridging Chemotherapy: Follicular Lymphoma, Mantle Cell Lymphoma, and CLL
24. Bridging Chemotherapy: Multiple Myeloma
25. Lymphodepleting Conditioning Regimens
26. Management of Cytokine Release Syndrome (CRS) and HLH
27. Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
28. Management of Myelotoxicity (Aplasia) and Infectious Complications
29. Management of Other Toxicities
30. ICU
31. Post-CAR-T Cell Therapy (Consolidation and Relapse): Acute Lymphoblastic Leukaemia
32. Post-CAR-T Cell Therapy (Consolidation and Relapse): Lymphoma
33. Post-CAR-T Cell Therapy (Consolidation and Relapse): Multiple Myeloma
34. Immune Monitoring
35. Long-Term Follow-Up and Late Effects
36. The Regulatory Framework for CAR-T Cells in Europe: Current Status and Foreseeable Changes AND Centre Qualification by Competent Authorities and Manufacturers
37. How Can Accreditation Bodies, Such as JACIE or FACT, Support Centres in Getting Qualified?
38. Educational Needs for Physicians
39. Education Needs for Nurses in Adult and Paediatric Units
40. Role of Pharmacists
41. Educational Needs for Cell Processing Facility Personnel
42. GoCART
43. Patient Referral
44. Treatment Coverage and Reimbursement
45. The Value of CAR-T-cell Immunotherapy in Cancer
46. What do Patients Want? The Importance of Patient-reported Outcomes

This first open access European CAR-T Handbook, co-promoted by the European Society for Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA), covers several aspects of CAR-T cell treatments, including the underlying biology, indications, management of side-effects, access and manufacturing issues. This book, written by leading experts in the field to enhance readers’ knowledge and practice skills, provides an unparalleled overview of the CAR-T cell technology and its  application in clinical care, to enhance readers’ knowledge and practice skills.